Abstract

Introduction. On August 5, 2026, the FDA authorized Moderna’s mFLUSIVA (mRNA-1010) for adults ≥50 years, extending annual lifelong influenza immunization to a genetic platform already shown to be hazardous to human health. The approval was bifurcated: adults 50 through 64 years received Traditional Approval on clinical efficacy, while adults 65 years and older, the stratum bearing 70% to 85% of U.S. influenza mortality, received Accelerated Approval on hemagglutination inhibition titres as a surrogate endpoint. We examined whether the evidentiary basis for this decision supports licensure, and what the platform-level molecular literature implies for indefinite annual redosing.

Methods. We reanalyzed the efficacy and safety data in the FDA Vaccines and Related Biological Products Advisory Committee briefing document on an absolute risk scale, calculating absolute risk differences, numbers needed to vaccinate (NNV), numbers needed to harm (NNH), unadjusted risk ratios with 95% confidence intervals, and the ratio of harms incurred to benefits obtained, stratified by outcome severity, age group, baseline risk status, individual solicited symptom, severity grade, and influenza strain. No influenza-mortality endpoint was specified or collected anywhere in the program, so no estimate of mortality benefit was possible.

Results. Neither pivotal trial included a placebo arm; therefore, all safety differences were measured against active influenza-vaccine comparators rather than background event rates. Compared with the standard-dose comparator in the pivotal efficacy trial, every solicited symptom was more frequent with mFLUSIVA. Unexplained deaths were more than twice as frequent among mFLUSIVA recipients: 23 versus 9 (RR, 2.55; 95% CI: 1.18, 5.52), increasing to 29 versus 12 when related fatal-event terms were pooled (RR, 2.42; 95% CI: 1.23, 4.73). Only one autopsy was performed across the entire clinical program, and it was in the comparator arm. Solicited adverse reactions occurred in 75.7% of mFLUSIVA recipients versus 46.7% of standard-dose comparator recipients, antipyretic or analgesic use in 28.5% versus 9.1%, and reactions preventing daily activity in 5.5% versus 0.9%. These corresponded to one additional affected recipient for every 3.4, 5.2, and 21.6 vaccinated, respectively. Fever was 6.65-fold more frequent (95% CI: 4.42, 10.01), chills 5.30-fold (4.42, 6.35), antipyretic or analgesic use 3.14-fold (2.77, 3.57), and injection-site pain 2.21-fold (2.08, 2.35; 65.8% vs 29.8%). Grade 3 systemic reactions overall were 6.15-fold more frequent with mFLUSIVA (95% CI: 4.11, 9.20). The largest Grade 3 disparities included injection-site pain at 26.84-fold (95% CI: 3.65, 197.4), chills at 15.41-fold (5.61, 42.30), local reactions overall at 12.67-fold (4.59, 35.02), and myalgia at 10.79-fold (4.98, 23.37). Reactogenicity did not attenuate with age: among adults ≥65 years, Grade 3 systemic and local reactions were 6.24-fold (3.31, 11.73) and 11.43-fold (2.70, 48.40) more frequent, respectively. In the separate trial against Fluzone High-Dose, the comparator preferentially recommended for older adults, Grade 3 systemic reactions were approximately four-fold more frequent with mFLUSIVA (RR, 4.08; 95% CI: 2.65, 6.29). Serious adverse events were more frequent in the pivotal trial considered alone (RR, 1.16; 95% CI: 1.02, 1.33), and urinary tract infection serious adverse events were more frequent in the pooled database (38 vs 22; RR, 1.73; 95% CI: 1.02, 2.92). Treating investigators attributed serious adverse events to the vaccine three times as often in the mFLUSIVA arm (9 vs 3) and adverse events of special interest more than twice as often (5 vs 2). Against this harm burden, the absolute clinical benefit was small. The overall risk of influenza-like illness was small, at 2.4%. Relative vaccine efficacy against RT-PCR-confirmed influenza-like illness was 26.6% (95% CI: 16.7, 35.4) over a single season against a non-preferred standard-dose comparator. On an absolute scale, 137 vaccinations were required to avert one confirmed influenza-like illness, 1,003 to avert one higher-level-care encounter, and 5,017 to avert one hospitalization. Benefit was smallest in those at greatest risk, with the NNV rising to 180 in adults ≥75 years and 168 in participants with at least one high-risk condition. Among the 5,017 mFLUSIVA recipients required to avert one influenza hospitalization, approximately 3,798 experienced a solicited adverse reaction (1,454 additional relative to comparator) and 278 experienced a Grade 3 systemic reaction severe enough to prevent daily activity (233 additional), alongside approximately 2 excess unexplained deaths. No properly adjudicated influenza-mortality endpoint was specified, collected, or reported anywhere in the program, leaving no estimate of mortality benefit for this critical outcome.

Conclusion. The mFLUSIVA approval should be withdrawn for both age indications and distribution halted. The risk-benefit profile is extremely unfavorable. Relative to a licensed standard-dose influenza vaccine, averting a single influenza hospitalization required 5,017 vaccinations and was accompanied by roughly 1,454 additional solicited adverse reactions, 233 of them severe enough to prevent daily activity, and by approximately 2 excess unexplained deaths. The outcome this product class exists to prevent was never measured, the mortality signal that did emerge was rendered permanently unresolvable because the single autopsy performed across the program was in the comparator arm, and the Phase 4 study required to verify benefit is a noninferiority trial powered on the explicit assumption that the benefit is zero. Extending a platform with documented genomic, ribosomal, and proteostatic liabilities to annual lifelong administration compounds these risks across decades, and the encoded antigen is itself a sialic-acid-binding fusogen whose expression level, duration, biodistribution, and fusogenic competence were never measured. The benefit-risk relationship did not support licensure when it was granted and does not support it now.